Cargando…

BioBanking as the central tool for translational medicine CTM issue 2013

THE IMPACT OF MAPPING THE HUMAN PROTEOME: Globally, the health care organizations are under resource and cost constrains due to the increasing number of patients that are due to a fast increase of the 65+ age group requiring extensive medical hospitalization and treatments. Hospitals worldwide striv...

Descripción completa

Detalles Bibliográficos
Autor principal: Marko-Varga, György
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585702/
https://www.ncbi.nlm.nih.gov/pubmed/23388084
http://dx.doi.org/10.1186/2001-1326-2-4
_version_ 1782261189596676096
author Marko-Varga, György
author_facet Marko-Varga, György
author_sort Marko-Varga, György
collection PubMed
description THE IMPACT OF MAPPING THE HUMAN PROTEOME: Globally, the health care organizations are under resource and cost constrains due to the increasing number of patients that are due to a fast increase of the 65+ age group requiring extensive medical hospitalization and treatments. Hospitals worldwide strive to seek the best cure for patients, suffering from various diseases. A consequence of these global changes, of healthy populations in relation to patients forms the basis for the build of large and centralized biobank facilities, with strategies where the search for an understanding of diseases at a molecular level is at heart. The efforts made lies within large governmental resource allocations where patient centers are collecting samples from clinical study participants in order to try to discover universal expression patterns and molecular signatures of disease and disease stages. Most developments in this area are aimed towards the discovery, and understanding diagnosis implementations. By providing the right treatment alternatives for patients care, at the right time point i.e., at a given disease stage development becomes a major goal where pharmaceutical industry, academia and the health care sector joins forces in large clinical epidemiological, population-, and disease based studies. This becomes a clear strategic link to the enhancement and prospects for personalized medicines and target directed diagnosis developments (Companion Diagnostics), which require coordinated efforts across a wide range of disciplines. Currently, companion diagnostics is at the core of the personalized medicine paradigm shift. It will identify patients who are most likely to benefit from a particular therapeutic product, as well as identify patients likely to be at increased risk for serious adverse reactions as a result of treatment with a particular therapeutic agent. It is predicted that more than half of all new drugs will require a companion diagnostic, which opens up for an endeavor for Proteomics research implementations.
format Online
Article
Text
id pubmed-3585702
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer
record_format MEDLINE/PubMed
spelling pubmed-35857022013-03-05 BioBanking as the central tool for translational medicine CTM issue 2013 Marko-Varga, György Clin Transl Med Editorial THE IMPACT OF MAPPING THE HUMAN PROTEOME: Globally, the health care organizations are under resource and cost constrains due to the increasing number of patients that are due to a fast increase of the 65+ age group requiring extensive medical hospitalization and treatments. Hospitals worldwide strive to seek the best cure for patients, suffering from various diseases. A consequence of these global changes, of healthy populations in relation to patients forms the basis for the build of large and centralized biobank facilities, with strategies where the search for an understanding of diseases at a molecular level is at heart. The efforts made lies within large governmental resource allocations where patient centers are collecting samples from clinical study participants in order to try to discover universal expression patterns and molecular signatures of disease and disease stages. Most developments in this area are aimed towards the discovery, and understanding diagnosis implementations. By providing the right treatment alternatives for patients care, at the right time point i.e., at a given disease stage development becomes a major goal where pharmaceutical industry, academia and the health care sector joins forces in large clinical epidemiological, population-, and disease based studies. This becomes a clear strategic link to the enhancement and prospects for personalized medicines and target directed diagnosis developments (Companion Diagnostics), which require coordinated efforts across a wide range of disciplines. Currently, companion diagnostics is at the core of the personalized medicine paradigm shift. It will identify patients who are most likely to benefit from a particular therapeutic product, as well as identify patients likely to be at increased risk for serious adverse reactions as a result of treatment with a particular therapeutic agent. It is predicted that more than half of all new drugs will require a companion diagnostic, which opens up for an endeavor for Proteomics research implementations. Springer 2013-02-06 /pmc/articles/PMC3585702/ /pubmed/23388084 http://dx.doi.org/10.1186/2001-1326-2-4 Text en Copyright ©2013 Marko-Varga; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Editorial
Marko-Varga, György
BioBanking as the central tool for translational medicine CTM issue 2013
title BioBanking as the central tool for translational medicine CTM issue 2013
title_full BioBanking as the central tool for translational medicine CTM issue 2013
title_fullStr BioBanking as the central tool for translational medicine CTM issue 2013
title_full_unstemmed BioBanking as the central tool for translational medicine CTM issue 2013
title_short BioBanking as the central tool for translational medicine CTM issue 2013
title_sort biobanking as the central tool for translational medicine ctm issue 2013
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585702/
https://www.ncbi.nlm.nih.gov/pubmed/23388084
http://dx.doi.org/10.1186/2001-1326-2-4
work_keys_str_mv AT markovargagyorgy biobankingasthecentraltoolfortranslationalmedicinectmissue2013